You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023138010
Dec 20233006
Jan 20242901
Feb 20241201
Mar 20241400
Apr 20242201
May 20242600
Jun 20245402
Jul 20242202
Aug 20242204
Sep 20241802
Oct 20241803
Nov 20245003
Dec 20242606
Jan 20253606
Feb 20251606
Mar 2025001
Apr 2025001
May 2025002
Jun 2025104
Total534061